GYRE · Gyre Therapeutics Inc
United States · RS rating 13 · As of 2026-11-03
| Price | 4.44 USD |
|---|---|
| 1-day change | -6.1% |
| RS rating (overall / 1M / 3M / 12M) | 13 / 7 / 22 / 25 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 20 / 4 / 17 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -20.0% |
| Sales growth Q/Q | +21.7% |
| Distance from 52-week high | +49.3% |
| Market cap (USD) | $679.4M |